Metformin Cost in Wisconsin 2026

What Does Metformin Actually Cost in Wisconsin Right Now?

Generic metformin at Wisconsin retail pharmacies averages about $8 per month cash-pay in 2026, making it one of the most affordable prescription drugs in the state. The manufacturer list price sits near $40 per month, but almost no patient pays that figure at the pharmacy counter. Discount programs, Medicaid, and 503A compounding can each push that number lower still.

The gap between list price and street price exists because metformin has been off-patent for decades. Multiple manufacturers compete, and large pharmacy chains negotiate aggressively. A 30-day supply of metformin hydrochloride 500 mg tablets (generic) at a major Wisconsin retailer (Walgreens, CVS, Costco, or a local independent) typically runs between $4 and $12 depending on the specific tablet strength and quantity dispensed. Metformin's FDA-approved labeling confirms it is available in 500 mg, 850 mg, and 1 to 000 mg tablet strengths.

Extended-release formulations (metformin ER or XR) carry a modest premium, sometimes $10, $18 per month cash-pay, because fewer generics compete in that segment. Patients prescribed metformin ER for gastrointestinal tolerability reasons should ask their pharmacist specifically for the generic extended-release version and confirm the price before the prescription is filled.

The UKPDS 34 trial (N=1,704) established metformin as a first-line agent in overweight patients with type 2 diabetes, showing a 36% reduction in diabetes-related mortality compared with diet alone, which cemented its position on virtually every national formulary. UKPDS 34, Lancet 1998. That clinical track record, combined with off-patent status, keeps Wisconsin prices low.

Wisconsin Medicaid (ForwardHealth) Coverage for Metformin

Wisconsin Medicaid, administered under the ForwardHealth program, covers metformin for type 2 diabetes with prior authorization (PA). The PA requirement is not automatic, but it is routinely approved for patients who meet standard diagnostic criteria. Most prescribers in Wisconsin are familiar with the ForwardHealth PA process, and approvals typically take one to three business days.

ForwardHealth's preferred drug list (PDL) places metformin in the oral antidiabetic category. The American Diabetes Association's 2024 Standards of Care in Diabetes designates metformin as a first-line pharmacologic agent for type 2 diabetes management. Because metformin aligns with ADA first-line guidance, PA approval rates in Wisconsin Medicaid are high when the clinical documentation is complete.

Patients on Wisconsin Medicaid pay zero or minimal copays for Tier 1 generics once prior authorization is approved. Metformin ER may require a separate PA step or a step-therapy attestation confirming that immediate-release metformin was trialed first.

Prediabetes coverage under Wisconsin Medicaid is narrower. ForwardHealth does not consistently cover metformin for prediabetes alone without additional documentation. The ADA's 2024 guidelines state that metformin therapy "should be considered" for high-risk prediabetes patients, particularly those with BMI <35 kg/m², but state Medicaid programs vary in how they operationalize that recommendation. ADA Standards of Care 2024, Section 3.

Commercial Insurance Coverage in Wisconsin

Most commercial health plans sold in Wisconsin place generic metformin on Tier 1 of their formulary, meaning the copay is typically $0, $10 per 30-day fill. Wisconsin's ACA marketplace plans (offered through HealthCare.gov and the state exchange) are required to cover preventive services at no cost-sharing, and the USPSTF recommends metformin for diabetes prevention in adults with prediabetes who are at high risk. USPSTF Prediabetes and Type 2 Diabetes Prevention Recommendation, 2021.

Employer-sponsored plans in Wisconsin (Blue Cross Blue Shield of Wisconsin, Quartz, Dean Health Plan, Common Ground Healthcare Cooperative, and Security Health Plan, among others) almost universally list generic metformin on Tier 1. Patients who find metformin on a higher tier should request a formulary exception, citing the drug's first-line ADA status and the FDA-approved generic availability, which gives pharmacists and physicians a straightforward path to a successful exception appeal.

Medicare Part D also covers metformin. Under the Inflation Reduction Act's drug pricing provisions, generic drugs in Medicare Part D are subject to a $2 or less copay cap under the low-income subsidy (LIS/Extra Help) program. CMS Medicare Part D Low-Income Subsidy overview. Wisconsin seniors enrolled in Extra Help may pay as little as $1.45 per fill for metformin.

Compounded Metformin in Wisconsin: What Is Legal?

Compounded metformin from a 503A pharmacy is legal in Wisconsin. A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescription. The FDA's 503A compounding framework is codified under 21 U.S.C. § 503A. Wisconsin pharmacies operating under 503A status can compound metformin in custom doses, alternative delivery forms, or formulations that address specific patient needs documented by the prescribing clinician.

Why would anyone compound a drug that costs $8 per month off the shelf? There are two practical reasons. First, some patients need doses or formulations not commercially available, for example a liquid suspension for patients with swallowing difficulties. Second, when metformin is compounded as part of a broader metabolic or longevity protocol through a telehealth provider, the compound may be dispensed at $0 direct out-of-pocket cost to the patient under certain subscription or membership models.

503B outsourcing facilities, by contrast, compound in bulk without patient-specific prescriptions and must register with the FDA. FDA 503B Outsourcing Facility registration database. Metformin is not on the FDA's current shortage list, which means 503B facilities face additional restrictions on compounding commercially available drugs. Patients in Wisconsin who receive compounded metformin should confirm their pharmacy operates under 503A and holds a current Wisconsin Pharmacy Examining Board license.

Compounded metformin is not bioequivalent-certified the way FDA-approved generics are. The clinical evidence base, including UKPDS 34 and the Diabetes Prevention Program (DPP) trial (N=3,234 to 31% reduction in diabetes incidence with metformin vs. placebo over 2.8 years), was built on standard oral tablet formulations. DPP Research Group, NEJM 2002. Patients switching between formulations should have A1c and fasting glucose monitored within 90 days of any change.

The Cheapest Ways to Get Metformin in Wisconsin

Several concrete options exist for Wisconsin residents who pay cash or have high-deductible coverage.

GoodRx and similar discount cards. GoodRx, RxSaver, and Blink Health negotiate discount rates with pharmacy benefit managers. At Wisconsin Walgreens and CVS locations, GoodRx prices for metformin 500 mg (60 tablets, 30-day supply) have ranged from $4 to $9 in early 2025. These prices fluctuate by zip code. Appleton, Green Bay, Milwaukee, and Madison residents may see slightly different rates because of regional pharmacy contracting.

Walmart $4 generic program. Walmart's generic drug list includes metformin at $4 for a 30-day supply and $10 for a 90-day supply at Wisconsin Walmart pharmacy locations. No membership or insurance is required. Walmart's $4 prescription program information page.

Kroger (Pick 'n Save / Roundy's) free generic program. Pick 'n Save pharmacy locations in Wisconsin have offered metformin free of charge under certain loyalty program tiers. Patients should call their local Pick 'n Save pharmacy to confirm current program status, as these programs can change without advance notice.

90-day supply fills. Filling a 90-day supply instead of 30-day fills reduces per-unit dispensing fees. At Costco Wisconsin locations, a 90-day supply of generic metformin 500 mg (180 tablets) costs approximately $10, $14 cash-pay. Costco pharmacy does not require a Costco membership for prescription purchases.

Mail-order pharmacies. Wisconsin-licensed mail-order pharmacies (including Amazon Pharmacy) typically price 90-day supplies of metformin at $10, $15 delivered. Amazon Pharmacy's RxPass program, at $5 per month, includes metformin for Prime members. Amazon Pharmacy RxPass terms.

Patient assistance programs. Because metformin is generic, brand-name manufacturer patient assistance programs do not apply. However, NeedyMeds.org and RxAssist.org maintain lists of state-specific and national programs for Wisconsin residents who meet income criteria.

Telehealth Prescribing of Metformin in Wisconsin

Telehealth prescribing of metformin is legal in Wisconsin as of 2025 to 2026. Wisconsin participated in the federal public-health-emergency telehealth flexibilities that allowed controlled substances via telemedicine, but metformin is not a controlled substance, so it faces no additional federal restrictions. A Wisconsin-licensed physician or advanced practice prescriber (APP) can issue a metformin prescription following a synchronous audio-video visit, and in some cases an asynchronous evaluation.

The Wisconsin Medical Examining Board and the Wisconsin Pharmacy Examining Board have not enacted specific restrictions on telehealth prescribing of non-controlled medications. Wisconsin Department of Safety and Professional Services, Telemedicine guidance. Standard informed-consent documentation and appropriate prescriber-patient relationship requirements still apply.

Telehealth platforms that serve Wisconsin residents, including HealthRX and national services such as Teladoc Health, have offered metformin prescriptions for type 2 diabetes and, in some cases, off-label prediabetes or weight-management protocols. Patients should confirm the platform's prescriber is licensed in Wisconsin, that the pharmacy fulfilling the prescription is Wisconsin-licensed or licensed in the patient's state of residence, and that lab work (fasting glucose, A1c, basic metabolic panel to assess renal function) has been reviewed before initiation. FDA labeling for metformin includes a contraindication for eGFR <30 mL/min/1.73m².

Metformin Dosing, Safety, and Monitoring in Wisconsin Clinical Practice

Metformin is dosed at 500, 2 to 000 mg per day in divided doses with meals to minimize gastrointestinal side effects. Most Wisconsin prescribers initiate at 500 mg twice daily and titrate upward over 4 to 8 weeks. The ADA's 2024 Standards of Care recommend titrating to the maximally tolerated dose within 3 months of initiation if glycemic targets are not met.

Renal monitoring is required. The FDA label specifies that metformin should be withheld before iodinated contrast procedures in patients with eGFR 30 to 60 mL/min/1.73m² and is contraindicated with eGFR <30 mL/min/1.73m². FDA drug safety communication on metformin and renal impairment, 2016. Wisconsin clinicians typically check a basic metabolic panel at baseline and annually, or more frequently in patients with chronic kidney disease.

Long-term metformin use is associated with vitamin B12 deficiency. A population-based analysis published in JAMA Internal Medicine (2019, N=232,444 metformin users) found that long-term users had a 7.1% higher rate of B12 deficiency compared with non-users, a statistically significant finding (P<0.001). Long-term metformin use and vitamin B12 deficiency, JAMA Intern Med 2019. Wisconsin providers managing patients on metformin for more than two years should check B12 annually, particularly in patients with peripheral neuropathy symptoms.

The Diabetes Prevention Program Outcomes Study (DPPOS), a 15-year follow-up of the original DPP cohort, showed that metformin maintained a 18% reduction in diabetes incidence versus placebo even at 15 years. DPPOS, Lancet 2009. This durability data supports long-term prescribing for high-risk prediabetes patients, which is relevant for Wisconsin clinicians navigating Medicaid PA requirements for that indication.

Why Metformin Remains First-Line Despite Newer Agents

GLP-1 receptor agonists (semaglutide, tirzepatide) and SGLT-2 inhibitors (empagliflozin, dapagliflozin) have cardiovascular and renal outcome data that metformin cannot match head-to-head for those specific endpoints. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% in high-risk type 2 diabetes patients. EMPA-REG OUTCOME, NEJM 2015. The LEADER trial (N=9,340) showed liraglutide reduced major adverse cardiovascular events (MACE) by 13% versus placebo. LEADER trial, NEJM 2016.

Despite this evidence, metformin retains first-line status in the ADA 2024 Standards of Care because of its safety record spanning more than 60 years of post-marketing surveillance, its neutral weight effect versus weight gain seen with sulfonylureas, its extremely low cost, and its absence of hypoglycemia risk as monotherapy. For the large population of Wisconsin patients with uncomplicated type 2 diabetes and no established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), metformin remains the evidence-supported starting point. ADA Standards of Care 2024, Section 9.

The cost difference is stark. Generic metformin at $8 per month versus semaglutide 0.5 to 2 mg weekly (Ozempic) at $800, $1,000 per month without insurance places metformin in a different category entirely for cost-sensitive Wisconsin patients and for ForwardHealth formulary management.

Metformin for Weight Management in Wisconsin: Off-Label Context

Metformin is sometimes prescribed off-label in Wisconsin for obesity-related insulin resistance, polycystic ovary syndrome (PCOS), and prevention of weight gain associated with antipsychotic medications. A 2020 meta-analysis in Obesity Reviews (18 RCTs, N=2,565) found that metformin produced a mean weight reduction of 1.3 kg versus placebo in non-diabetic adults with obesity. That effect size is modest compared with GLP-1 agents, but the cost differential makes it a reasonable adjunct in patients who cannot afford or access GLP-1 therapy.

PCOS management with metformin is supported by multiple trials. A Cochrane review (2017, 48 RCTs) found metformin improved ovulation rates and reduced androgen levels in women with PCOS, though the effect on live birth rates was less clear when compared directly with clomiphene. Cochrane review: metformin for PCOS. Wisconsin OB-GYN and reproductive endocrinology practices routinely prescribe metformin for PCOS off-label at doses of 1,500, 2 to 000 mg/day. Insurance coverage for this indication varies; patients should request an off-label use authorization letter from their prescriber when submitting claims.

How Wisconsin Compares to National Metformin Pricing

The $8 Wisconsin average cash-pay price aligns closely with the national median for generic metformin in 2026. States with fewer competing retail pharmacies (rural states, some Midwest markets) can see cash prices up to $15, $18 per month for the same 500 mg tablet quantity. Wisconsin's pharmacy density, particularly in Milwaukee, Madison, Green Bay, and Kenosha metropolitan areas, keeps competitive pressure on retail prices.

Wisconsin ranks above the national average for generic drug dispensing rates. The CDC's 2022 National Center for Health Statistics data shows that 90.7% of all U.S. outpatient prescriptions dispensed were generic, and Wisconsin's dispensing rate was comparable. CDC, National Center for Health Statistics, Health, United States 2022. High generic dispensing rates keep formulary rebates and cash-pay prices lower than in states where branded prescribing remains more common.

The state's Medicaid managed care organizations (MCOs), including Molina Healthcare of Wisconsin, Wisconsin's ForwardHealth Direct Data Entry (DDE) system, and WellCare of Wisconsin, all process metformin PA requests under the same ForwardHealth PDL criteria, so patients should not experience significant variation in approval outcomes depending on which MCO manages their Medicaid benefits.